secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2026-09-11T20:25:17+00:00
Accession:  0001193125-26-389318
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 2.01, 5.02, 9.01, 2.02, 3.02, 3.03, 5.01, 5.03, 5.05, 5.06, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Korsana (ex-Cyclerion) closes reverse merger with $380M PIPE; exchange ratio 0.2074
--------------------------------------------------------------------------------

- Closed Sept 8, 2026; exchange ratio 0.2074 Cyclerion shares per Korsana share; renamed Korsana Biosciences.
- PIPE financing raised ~$380M; 140.5M shares and 20.2M pre-funded warrants issued to investors pre-closing.
- Post-closing ownership: Cyclerion holders ~1.17%, Korsana holders ~98.83% fully diluted.
- 1-for-7 reverse stock split effective Sept 8; combined company had 55,051,271 shares outstanding (incl. prefunded warrants and Series B).
- Pre-merger Cyclerion shareholders receive one non-transferable CVR per share for 100% of net proceeds from sale of legacy Tisento and Akebia license assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000119312526389318/0001193125-26-389318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000119312526389318/d178159d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-389318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer